Ivosidenib is a targeted cancer drug. It is also known as Tibsovo. Azacitidine is a chemotherapy drug. It is also called Vidaza. You pronounce ivosidenib as i-voh-sih-deh-nib. And you pronounce ...

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Twenty-three patients received ...

Our Bureau, Mumbai Friday, June 6, 2025, 17:40 Hrs [IST] ...

They added that since venetoclax plus azacitidine became available, survival rates had substantially improved. Ivosidenib plus azacitidine would be a treatment option for the 6% to 10% of people with ...

The FDA approved ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia. Ivosidenib (Tibsovo, Servier) — an oral IDH1 inhibitor — had ...

PARIS and BOSTON, Dec. 11, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patient ...

About the PyramIDH Trial (NCT06465953) PyramIDH is a pivotal Phase 3, multicenter, open label, randomized clinical trial of TIBSOVO (ivosidenib tablets) monotherapy and azacitidine monotherapy in ...

Previous research identified ivosidenib combined with azacitidine as an effective and well-tolerated treatment of IDH1-mutant AML. An additional clinical trial found venetoclax and azacitidine ...

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Twenty-three patients received ivosidenib ...